Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ACOR

ACOR - Acorda Therapeutics Inc Stock Price, Fair Value and News

$0.26-0.02 (-7.14%)
Market Closed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

ACOR Price Action

ACOR RSI Chart

ACOR Valuation

ACOR Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ACOR Fundamentals

ACOR Revenue

ACOR Earnings

ACOR Profitability

ACOR Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024115.7M000
2023118.3M116.9M111.1M117.6M
2022122.7M122.0M124.1M118.6M
2021153.7M151.9M130.3M129.1M
2020176.4M159.9M165.3M153.0M
2019409.4M306.2M211.1M192.4M
2018575.1M588.9M590.7M471.4M
2017523.1M535.1M540.5M588.3M
2016508.7M522.5M509.9M519.6M
2015420.8M437.4M479.6M492.7M
2014345.1M355.2M376.2M401.5M
2013306.4M317.8M325.3M336.4M
2012302.2M312.6M297.0M305.8M
2011235.1M256.9M286.3M292.2M
201057.3M86.0M135.2M191.1M
2009053.8M54.2M54.7M
Get all data in R, Python etc through our Historical Stock Data APIs

About Acorda Therapeutics Inc

ACOR
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.
 CEO
 WEBSITEacorda.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers Specialty & Generic
 EMPLOYEES111